Boston-based Dana-Farber Cancer Institute posted an operating loss of $9.1 million (-0.9% margin) in the third quarter of fiscal 2026, compared with an operating loss of $2.6 million (-0.3% margin) in the same quarter last year, according to its Sept. 1 financial report.
Six things to know:
1. Total operating revenue was $1.1 billion in the three months ended June 30, up from $968.3 million during the same period last year. Net patient service revenue was $860.7 million, up from $764 million, which Dana-Farber attributed to growth in patient volume and pharmacy revenue.
2. Total operating expenses, excluding non-recurring items, were $1.1 billion in the quarter, up from $965.2 million during the same period last year. Patient service expenses totaled $727 million, up from $637.1 million. This increase was driven primarily by direct patient care costs of $712.3 million, up from $624.8 million, amid higher patient volume, compensation and drug costs, the system said.
3. Non-recurring items, net, reduced quarterly operating results by $20.8 million, up from a $5.7 million reduction in the same quarter last year. Dana-Farber attributes the year-to-date total of these costs primarily to planning expenses tied to a proposed clinical collaboration with Boston-based Beth Israel Deaconess Medical Center and construction of the Lavine Bekenstein Cancer Hospital at Dana-Farber, a 300-bed inpatient facility that broke ground in April 2026, as well as payouts under a voluntary early retirement plan announced in May 2025.
4. Net patient accounts receivable was $279.6 million as of June 30, down from $296.3 million at fiscal 2025 year-end (September 30), which Dana-Farber attributed to strong collection results across several large commercial payors and an increase in contractual allowances.
5. Dana-Farber recorded a net income of $153.1 million in the third quarter of fiscal 2026, up from $94.1 million during the same period last year, driven largely by investment gains of $150.9 million, up from $88.3 million.
6. Through the first nine months of fiscal 2026, Dana-Farber reported operating income of $52.1 million (1.7% margin), down from $58.9 million (2% margin) in the same period last year.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
